Our group is part of the Medical Chemistry Institute from the National Research Council (CSIC). We work on the design, synthesis, pharmacological evaluation and subsequent optimization of innovative multitarget drugs for the treatment of neurological diseases, including acute (stroke), degenerative (Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis, etc.) or psychiatric (major depression).

Currently, we are especially interested in the fields of Regenerative Medicine and Photopharmacology, through the development of neurogenic and / or neuroprotective agents and photoactivatable drugs, respectively.

Since 2012 our group has registered 3 patents and has published more than 35 articles in renowned scientific journals. We also collaborate with companies in the pharmaceutical sector through Technological Support Agreements (Eli Lilly, DignaBiotech), R&D Contracts (Noscira) and Confidentiality Agreements (Servier France, Janssen Spain and Esteve).

For more information about the research developed in our group you can visit also our website.